

Officers

Ehtisham Mahmud, MD, FSCAI
President

Cindy L. Grines, MD, MSCAI
President-Elect

Timothy D. Henry MD, MSCAI
Vice President

Peter L. Duffy, MD, MMM, FSCAI
Treasurer

David A. Cox, MD, MSCAI
Immediate Past President

January 3, 2020

Ms. Michelle Joshua
Mr. Michael Treitel
Inpatient PPS New Medical Services and Technologies
Division of Acute Care
Mailstop C4-08-06
Centers for Medicare and Medicaid Services
7500 Security Boulevard
Baltimore, MD 21244-1850

Trustees

Herbert D. Aronow, MD, MPH, FSCAI
Lyndon C. Box, MD, FSCAI
Ronald P. Caputo, MD, FSCAI
Shao-Liang Chen, MD, FSCAI
Dmitriy N. Feldman, MD, FSCAI
Howard C. Herrmann, MD, MSCAI
Frank F. Ing, MD, MSCAI
John C. Messenger, MD, FSCAI
Molly Szerlip, MD, FSCAI

Trustees for Life

Frank J. Hildner, MD, FSCAI
William C. Sheldon, MD, FSCAI

Francesca M. Dea, CAE
Chief Executive Officer

**Submitted electronically via newtech@CMS.hhs.gov;
michelle.joshua@cms.hhs.gov; micheal.treitel@cms.hhs.gov

RE: Medicare Program; Town Hall Meeting on the FY 2021 Applications for New Medical Services and Technologies Add-On Payments [CMS-1722-N]

Dear Ms. Joshua and Mr. Treitel:

The Society for Cardiovascular Angiography and Interventions (SCAI) is a non-profit professional association with over 5,000 members representing the majority of practicing interventional cardiologists and cardiac catheterization teams in the United States including those treating high-risk Acute Myocardial Infarction (AMI) patients. SCAI promotes excellence in invasive and interventional cardiovascular medicine through education, representation and the advancement of quality standards to enhance patient care.

SCAI urges CMS to grant NTAP for Supersaturated Oxygen (SSO₂) Therapy (DownStream® System)

SCAI finds TherOx's request for new tech add-on payment (NTAP) for "SSO₂ Therapy" (supersaturated oxygen therapy) used for ST-Elevation Myocardial Infarction (STEMI) cases where the anterior wall infarction impacts the left ventricle (LV) meets the established requirements for new tech add-on payment. Even after percutaneous coronary interventions (e.g., angioplasty, stenting), many AMI patients suffer irreversible damage to the heart muscle. SSO₂ Therapy, consisting of a 60-minute infusion of super oxygenated blood to the target ischemic area of the heart represents a novel, new therapy designed to salvage heart muscle and reduce infarct size supporting a substantial clinical improvement.

January 3, 2020

Page 2 of 2

In conclusion, SCAI appreciates the opportunity to provide comment to CMS on issues of high interest to the interventional cardiology community. If SCAI can be of any assistance as CMS continues to consider and review these issues, please do not hesitate to contact Mrs. Dawn R. Gray (Hopkins), Director of Reimbursement & Regulatory Affairs at (800) 253-4636, ext. 510 or dgray@scai.org.

Sincerely,



Ehtisham Mahmud, MD, FSCAI
SCAI President, 2019-2020

Ehtisham Mahmud, MD, FSCAI
President, Society for Cardiovascular Angiography and Interventions
Edith and William Perlman Chair in Cardiology
Professor and Division Chief, Cardiovascular Medicine
Executive Director, UCSD Cardiovascular Institute-Medicine
University of California, San Diego
Ph: (858) 657-8030
Fax: (858) 657-8032
email: emahmud@ucsd.edu

CC: Francesca Dea, CAE, SCAI
Lyndon Box, MD, FSCAI
Joaquin Cigarroa, MD, FSCAI
Ariel Gonzalez, Esq, SCAI
Dawn R. Gray (Hopkins), SCAI